Business Description
Aarti Pharmalabs Ltd
ISIN : INE0LRU01027
Total Employee Number:
3,005Compare
Compare
Traded in other countries / regions
543748.India IPO Date
2023-01-30Description
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | 1.89 | |||||
Interest Coverage | 6.35 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.73 | |||||
Beneish M-Score | -2.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.1 | |||||
3-Year EBITDA Growth Rate | 3.7 | |||||
3-Year EPS without NRI Growth Rate | -3 | |||||
3-Year Book Growth Rate | 10.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.11 | |||||
9-Day RSI | 61.8 | |||||
14-Day RSI | 57.63 | |||||
3-1 Month Momentum % | 1.15 | |||||
6-1 Month Momentum % | -13.69 | |||||
12-1 Month Momentum % | -29.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.49 | |||||
Quick Ratio | 0.81 | |||||
Cash Ratio | 0.01 | |||||
Days Inventory | 269.38 | |||||
Days Sales Outstanding | 108.92 | |||||
Days Payable | 130.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.57 | |||||
Dividend Payout Ratio | 0.19 | |||||
Forward Dividend Yield % | 0.57 | |||||
5-Year Yield-on-Cost % | 0.59 | |||||
Shareholder Yield % | -4.25 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.12 | |||||
Operating Margin % | 16.38 | |||||
Net Margin % | 10.25 | |||||
EBITDA Margin % | 21.98 | |||||
FCF Margin % | -10.24 | |||||
OCF Margin % | 14.4 | |||||
ROE % | 9.08 | |||||
ROA % | 5.8 | |||||
ROIC % | 7.78 | |||||
3-Year ROIIC % | 1.23 | |||||
ROC (Joel Greenblatt) % | 11.94 | |||||
ROCE % | 12.23 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 32.87 | |||||
Forward PE Ratio | 38.21 | |||||
PE Ratio without NRI | 32.5 | |||||
PS Ratio | 3.37 | |||||
PB Ratio | 2.88 | |||||
Price-to-Tangible-Book | 3.18 | |||||
Price-to-Operating-Cash-Flow | 23.43 | |||||
EV-to-EBIT | 24.05 | |||||
EV-to-EBITDA | 17.78 | |||||
EV-to-Revenue | 3.91 | |||||
EV-to-FCF | -37.64 | |||||
Price-to-GF-Value | 1.09 | |||||
Price-to-Graham-Number | 2.19 | |||||
| Price-to-Net-Current-Asset-Value | 158.76 | |||||
Earnings Yield (Greenblatt) % | 4.16 | |||||
FCF Yield % | -2.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aarti Pharmalabs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 18,194.424 | ||
| EPS (TTM) (₹) | 20.57 | ||
| Beta | 0.9565 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 0.79 | ||
| Volatility % | 42.48 | ||
| 14-Day RSI | 57.63 | ||
| 14-Day ATR (₹) | 25.040088 | ||
| 20-Day SMA (₹) | 660.25 | ||
| 12-1 Month Momentum % | -29.62 | ||
| 52-Week Range (₹) | 585 - 971 | ||
| Shares Outstanding (Mil) | 90.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aarti Pharmalabs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aarti Pharmalabs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 1.500000 Cash Dividend | 2026-02-16 | 709.20 (-0.11%) | ||
| INR 2.500000 Cash Dividend | 2025-09-15 | 926.35 (+1.24%) | ||
| INR 2.500000 Cash Dividend | 2025-02-14 | 736.20 (-0.37%) | ||
| INR 1.000000 Cash Dividend | 2024-07-31 | 615.10 (+2.02%) |
Show
Entries
Aarti Pharmalabs Ltd Frequently Asked Questions
What is Aarti Pharmalabs Ltd(NSE:AARTIPHARM)'s stock price today?
The current price of NSE:AARTIPHARM is ₹701.70. The 52 week high of NSE:AARTIPHARM is ₹971.00 and 52 week low is ₹585.00.
When is next earnings date of Aarti Pharmalabs Ltd(NSE:AARTIPHARM)?
The next earnings date of Aarti Pharmalabs Ltd(NSE:AARTIPHARM) is .
Does Aarti Pharmalabs Ltd(NSE:AARTIPHARM) pay dividends? If so, how much?
The Dividend Yield %  of Aarti Pharmalabs Ltd(NSE:AARTIPHARM) is 0.57% (As of Today), Highest Dividend Payout Ratio of Aarti Pharmalabs Ltd(NSE:AARTIPHARM) was 0.21. The lowest was 0.08. And the median was 0.12. The  Forward Dividend Yield % of Aarti Pharmalabs Ltd(NSE:AARTIPHARM) is 0.57%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Aarti Pharmalabs Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers